The rise of Sildenafil initially drove a surge for pharma, however recent shifts present a uncertain picture for shareholders. Generic versions are reducing profits, and persistent litigation add further difficulty to the equation. While certain companies might still see gains from related services, the broader trend suggests a measured approach to